Prospective Multicenter Study of Chemotherapy-Induced
Clostridium (Clostridioides) difficile
chemotherapy
diarrhea
lung cancer
prospective multicenter study
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
03
2021
accepted:
05
07
2021
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Diarrhea post-antibiotic use is primarily attributed to mucosal lesions induced by The presence of A total of 263 consecutive patients were enrolled in the study; grade 2 or higher diarrhea was observed in 22 patients (8.4%); CDI was confirmed in five of them (1.9%). The incidence of CDI was 22.7% of all diarrhea cases, and 50% of patients treated with PTX were CDI positive; the incidence of CDI was significantly higher in patients treated with PTX (P=0.039). Among the diarrhea cases, CDI patients had significantly worse ECOG performance status (PS) (P=0.043) and a significantly higher neutrophil count (P=0.028) than non-CDI patients. No CDI patients received antibiotics before cancer chemotherapy. Although diarrhea does not always affect a large portion of lung cancer chemotherapy recipients, clinicians should consider the possibility of CDI occurrence in lung cancer patients receiving chemotherapy, particularly PTX, without prior antibiotic exposure.
Sections du résumé
BACKGROUND
BACKGROUND
Diarrhea post-antibiotic use is primarily attributed to mucosal lesions induced by
METHODS
METHODS
The presence of
RESULTS
RESULTS
A total of 263 consecutive patients were enrolled in the study; grade 2 or higher diarrhea was observed in 22 patients (8.4%); CDI was confirmed in five of them (1.9%). The incidence of CDI was 22.7% of all diarrhea cases, and 50% of patients treated with PTX were CDI positive; the incidence of CDI was significantly higher in patients treated with PTX (P=0.039). Among the diarrhea cases, CDI patients had significantly worse ECOG performance status (PS) (P=0.043) and a significantly higher neutrophil count (P=0.028) than non-CDI patients. No CDI patients received antibiotics before cancer chemotherapy.
CONCLUSIONS
CONCLUSIONS
Although diarrhea does not always affect a large portion of lung cancer chemotherapy recipients, clinicians should consider the possibility of CDI occurrence in lung cancer patients receiving chemotherapy, particularly PTX, without prior antibiotic exposure.
Identifiants
pubmed: 34336670
doi: 10.3389/fonc.2021.685320
pmc: PMC8320591
doi:
Types de publication
Journal Article
Langues
eng
Pagination
685320Informations de copyright
Copyright © 2021 Toi, Kobayashi, Harada, Nakagawa, Mori, Kuda and Sugawara.
Déclaration de conflit d'intérêts
SS reports lecture fees from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, AstraZeneca, Chugai Pharma, Nippon Boehringer Ingelheim, Pfizer, Taiho Pharmaceutical, Eli Lilly and Company, Novartis, Yakult Honsha, and Kyowa Hakko Kirin. YT reports lecture fees from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, AstraZeneca, and Taiho Pharmaceutical. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Int J Clin Oncol. 2018 Dec;23(6):1046-1051
pubmed: 29876691
Recent Pat Antiinfect Drug Discov. 2012 Aug;7(2):157-70
pubmed: 22792862
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
World J Gastrointest Oncol. 2010 Oct 15;2(10):390-4
pubmed: 21160890
Jpn J Infect Dis. 2013;66(5):379-82
pubmed: 24047734
Clin Infect Dis. 1998 May;26(5):1027-34; quiz 1035-6
pubmed: 9597221
Oncoimmunology. 2017 Jul 5;6(10):e1344805
pubmed: 29123955
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Clin Infect Dis. 2001 Sep 15;33(6):786-91
pubmed: 11512083
ESMO Open. 2018 Jan 13;3(1):e000278
pubmed: 29387476
Infect Dis Ther. 2018 Mar;7(1):39-70
pubmed: 29441500
Chest. 2007 Mar;131(3):840-846
pubmed: 17356101
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472
pubmed: 31805526
N Engl J Med. 2017 Jan 26;376(4):305-317
pubmed: 28121498
J Clin Oncol. 2004 Jul 15;22(14):2918-26
pubmed: 15254061
Gynecol Oncol. 1998 Oct;71(1):104-7
pubmed: 9784328
N Engl J Med. 2011 Feb 3;364(5):422-31
pubmed: 21288078
BMC Cancer. 2011 May 02;11:159
pubmed: 21535895
BMC Infect Dis. 2014 Sep 29;14:523
pubmed: 25267108
N Engl J Med. 2015 Apr 16;372(16):1539-48
pubmed: 25875259
Clin Infect Dis. 1993 Jul;17(1):109-13
pubmed: 8353229
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Curr Med Chem. 2016;23(39):4442-4449
pubmed: 27804875
Support Care Cancer. 2015 Jun;23(6):1569-77
pubmed: 25410088
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55
pubmed: 20307191
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
Obstet Gynecol Int. 2010;2010:
pubmed: 20706661